Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to modernization of prescribing information for physicians and pharmacists;
Improved Access to Affordable Medications Act, S. 1120;
Increasing Transparency in Generic Drug Applications, S.775 and HR 3839;
Part D Formulary Design and Generic Drug Tiering;
Prescription Information Modernization Act, HR 1503; and
Presidents Emergency Plan for AIDS Relief Reauthorization.
Issues related to Inter Partes Review and patent policy generally;
Preserve Access to Affordable Generics and Biosimilars Act, S.142;
Affordable Prescriptions for Patients Act, S. 150
Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023 (S. 79 and HR 1717) and Medication Affordability and Patent Integrity Act (S.2780 and HR 5429);
PREVAIL Act (S.2220 and HR 4370).
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act, H.R. 1352.
Monitor issues related to antitrust and competition.
Issues related to e-labeling;
monitor issues related to Pharmacy Benefit Manager Transparency Act, S.127.
Duration: January 1, 2015
to
present
General Issues: Health Issues , Copyright/Patent/Trademark , Budget/Appropriations , Medicare/Medicaid , Labor Issues/Antitrust/Workplace , Pharmacy , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code
Spending: about $2,430,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: U.S. Senate, House of Representatives, Patent & Trademark Office (PTO), White House Office
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Cindy Brown Chief of Staff, Rep. Ron Kind
Ashley Davis Special Asst. to the Homeland Security Director
Ashley Davis cont. Deputy Director of Management and Adminstration, EOP
Malloy McDaniel Policy Advisor, Senate Minority Leader Mitch McConnell
Malloy McDaniel cont. Whip Liaison, Senate Majority Whip Mitch McConnell
Floor Assistant, Senate Majority Leader Trent Lott
Cloakroom Assistant, Office of the Republican Secretary
Kristi Remington Deputy Assistant Attorney General, US Department of Justice
Kristi Remington cont. Senior Counsel, House Government Reform Committee
Shimon Stein Senior Policy Advisor, House Majority Leader Eric Cantor
Shimon Stein cont. Program Manager, US Department of Justice
Legislative Correspondent, Senator John Ashcroft
Paid Intern, Congressman Robert Aderholt
Craig Kalkut Staff Director/Chief Counsel, Senate Judiciary Committee; Analyst, Senate Budget Committee; Counsel, Legislative Assistant, Special Assistant to Chief Staff, Senator Kent Conrad
Christopher Buki Staff Assistant/Legislative Correspondent, Representative John Culberson; Legislative Assistant/Senior Legislative Assistant, Representative Bill Shuster; Legislative Director/Deputy Chief of Staff, Representative David McKinley
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on April 22.
Original Filing: 301573158.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to modernization of prescribing information for physicians and pharmacists;
Improved Access to Affordable Medications Act, S. 1120;
Increasing Transparency in Generic Drug Applications, S.775 and HR 3839;
Part D Formulary Design and Generic Drug Tiering;
Prescription Information Modernization Act, HR 1503; and
Presidents Emergency Plan for AIDS Relief Reauthorization.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review and patent policy generally;
Preserve Access to Affordable Generics and Biosimilars Act, S.142;
Affordable Prescriptions for Patients Act, S. 150
Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023 (S. 79 and HR 1717) and Medication Affordability and Patent Integrity Act (S.2780 and HR 5429);
PREVAIL Act (S.2220 and HR 4370).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act, H.R. 1352.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to e-labeling;
monitor issues related to Pharmacy Benefit Manager Transparency Act, S.127.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on Jan. 15.
Original Filing: 301524821.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to modernization of prescribing information for physicians and pharmacists;
Improved Access to Affordable Medications Act, S. 1120;
Increasing Transparency in Generic Drug Applications, S.775 and HR 3839;
Part D Formulary Design and Generic Drug Tiering;
Prescription Information Modernization Act, HR 1503; and
Presidents Emergency Plan for AIDS Relief Reauthorization.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review and patent policy generally;
Preserve Access to Affordable Generics and Biosimilars Act, S.142;
Affordable Prescriptions for Patients Act, S. 150
Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023 (S. 79 and HR 1717) and Medication Affordability and Patent Integrity Act (S.2780 and HR 5429);
PREVAIL Act (S.2220 and HR 4370).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act, H.R. 1352.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to e-labeling;
monitor issues related to Pharmacy Benefit Manager Transparency Act, S.127.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on Oct. 20, 2023.
Original Filing: 301515480.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to modernization of prescribing information for physicians and pharmacists;
Improved Access to Affordable Medications Act, S. 1120;
Increasing Transparency in Generic Drug Applications, S.775 and HR 3839;
Part D Formulary Design and Generic Drug Tiering;
Prescription Information Modernization Act, HR 1503; and
Presidents Emergency Plan for AIDS Relief Reauthorization.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review and patent policy generally;
Preserve Access to Affordable Generics and Biosimilars Act, S.142;
Affordable Prescriptions for Patients Act, S. 150
Issues related to FDA and PTO coordination, including, Interagency Patent Coordination and Improvement Act of 2023 (S. 79 and HR 1717) and Medication Affordability and Patent Integrity Act (S. 2780 and HR 5429).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act, H.R. 1352.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to e-labeling;
monitor issues related to Pharmacy Benefit Manager Transparency Act, S.127.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on July 20, 2023.
Original Filing: 301488864.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to modernization of prescribing information for physicians and pharmacists;
Improved Access to Affordable Medications Act, S. 1120; and
Increasing Transparency in Generic Drug Applications, S.775 and HR 3839.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review and patent policy generally;
Preserve Access to Affordable Generics and Biosimilars Act, S.142;
Affordable Prescriptions for Patients Act, S. 150.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act, H.R. 1352.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to e-labeling;
monitor issues related to Pharmacy Benefit Manager Transparency Act, S.127.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on April 19, 2023.
Original Filing: 301459555.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to modernization of prescribing information for physicians and pharmacists;
Improved Access to Affordable Medications Act, S. 1120; and
Increasing Transparency in Generic Drug Applications, S.775.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review and patent policy generally;
Preserve Access to Affordable Generics and Biosimilars Act, S.142;
Affordable Prescriptions for Patients Act, S. 150.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act, H.R. 1352.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to e-labeling;
monitor issues related to Pharmacy Benefit Manager Transparency Act, S.127.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on Jan. 20, 2023.
Original Filing: 301443747.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to FDA facility inspections, including HR 7006, Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act;
issues related to modernization of prescribing information for physicians and pharmacists;
HR 6973, Enhanced Access to Affordable Medicines Act of 2022;
HR 7032, Increasing Transparency in Generic Drug Applications Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review and patent policy generally;
Preserving Access to Affordable Generics and Biosimilars Act, S. 1428, H.R. 2891;
Affordable Prescriptions for Patients Act, S.1435, H.R. 2873;
Restoring the America Invents Act, S. 2891.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D, including the Ensuring Access to Lower Cost Medicines for Seniors Act, H.R. 2846;
issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act of 2021, H.R. 2869 and S. 1427;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to e-labeling;
Generic Drug User Fee Amendments reauthorization;
monitor issues related to Pharmacy Benefit Manager Transparency Act of 2022 (S.4293).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on Oct. 17, 2022.
Original Filing: 301406253.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to FDA facility inspections, including HR 7006, Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act;
issues related to modernization of prescribing information for physicians and pharmacists;
HR 6973, Enhanced Access to Affordable Medicines Act of 2022;
HR 7032, Increasing Transparency in Generic Drug Applications Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review and patent policy generally;
Preserving Access to Affordable Generics and Biosimilars Act, S. 1428, H.R. 2891;
Affordable Prescriptions for Patients Act, S.1435, H.R. 2873;
Restoring the America Invents Act, S. 2891.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty);
monitor issues related to the 2022 budget process and reconciliation, including the Inflation Reduction Act, HR 5376.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D, including the Ensuring Access to Lower Cost Medicines for Seniors Act, H.R. 2846;
issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act of 2021, H.R. 2869 and S. 1427;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to e-labeling;
monitor issues related to Pharmacy Benefit Manager Transparency Act of 2022 (S.4293).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on July 21, 2022.
Original Filing: 301396783.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to FDA facility inspections, including HR 7006, Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act;
issues related to modernization of prescribing information for physicians and pharmacists;
HR 6973, Enhanced Access to Affordable Medicines Act of 2022;
HR 7032, Increasing Transparency in Generic Drug Applications Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review and patent policy generally;
Preserving Access to Affordable Generics and Biosimilars Act, S. 1428, H.R. 2891;
Affordable Prescriptions for Patients Act, S.1435, H.R. 2873;
Restoring the America Invents Act, S. 2891.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty);
monitor issues related to the 2022 budget process and reconciliation, including the Build Back Better Act, HR 5376.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D, including the Ensuring Access to Lower Cost Medicines for Seniors Act, H.R. 2846;
issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act of 2021, H.R. 2869 and S. 1427;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Issues related to e-labeling;
monitor issues related to Pharmacy Benefit Manager Transparency Act of 2022 (S.4293).
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on April 20, 2022.
Original Filing: 301371564.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to FDA facility inspections, including HR 7006, Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act;
issues related to modernization of prescribing information for physicians and pharmacists;
HR 6973, Enhanced Access to Affordable Medicines Act of 2022;
HR 7032, Increasing Transparency in Generic Drug Applications Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to Inter Partes Review and patent reform generally;
Preserving Access to Affordable Generics and Biosimilars Act, S. 1428, H.R. 2891;
Affordable Prescriptions for Patients Act, S.1435, H.R. 2873;
Restoring the America Invents Act, S. 2891.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty);
monitor issues related to the 2022 budget process and reconciliation, including the Build Back Better Act, HR 5376.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D, including the Ensuring Access to Lower Cost Medicines for Seniors Act, H.R. 2846;
issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act of 2021, H.R. 2869 and S. 1427;
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
4th Quarter, 2021
In Q4, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on Jan. 20, 2022.
Original Filing: 301338767.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to modernization of prescribing information for physicians and pharmacists.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to Inter Partes Review and patent reform generally;
Preserving Access to Affordable Generics and Biosimilars Act (S. 1428, H.R. 2891);
Affordable Prescriptions for Patients Act (S.1435, H.R. 2873);
Restoring the America Invents Act (S. 2891).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty);
monitor issues related to the 2022 budget process and reconciliation, including the Build Back Better Act, HR 5376.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D, including the Ensuring Access to Lower Cost Medicines for Seniors Act (H.R. 2846);
issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act of 2021 (H.R. 2869 and S. 1427);
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
3rd Quarter, 2021
In Q3, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313250.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to modernization of prescribing information for physicians and pharmacists.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to Inter Partes Review and patent reform generally;
Preserving Access to Affordable Generics and Biosimilars Act (S. 1428 and H.R. 2891);
Affordable Prescriptions for Patients Act (S.1435);
Restoring the America Invents Act (S. 2891).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty);
monitor issues related to the 2022 budget process and reconciliation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D, including the Ensuring Access to Lower Cost Medicines for Seniors Act (H.R. 2846);
issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act of 2021 (H.R. 2869 and S. 1427);
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2021
In Q2, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on July 20, 2021.
Original Filing: 301289138.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to modernization of prescribing information for physicians and pharmacists.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to Inter Partes Review and patent reform generally.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D, including the Ensuring Access to Lower Cost Medicines for Seniors Act (H.R. 2846);
issues related to access to biosimilar biological products in Medicare Part B, including the Increasing Access to Biosimilars Act of 2021 (H.R. 2869 and S. 1427);
issues related to rebate walls.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to antitrust and competition.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2021
In Q1, West Front Strategies LLC lobbied for Viatris Inc. , earning $70,000. The report was filed on April 20, 2021.
Original Filing: 301268052.xml
Lobbying Issues
Issues related to drug pricing;
issues related to pharmaceutical supply chain;
issues related to modernization of prescribing information for physicians and pharmacists.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor issues related to Inter Partes Review.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilar biological products in Part D;
issues related to access to biosimilar biological products in Medicare Part B.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, West Front Strategies LLC lobbied for Viatris Inc. (formerly Mylan, Inc.) , earning $70,000. The report was filed on Jan. 21, 2021.
Original Filing: 301245922.xml
Lobbying Issues
Issues related to drug pricing;
S. 64, Preserve Access to Affordable Generics and Biosimilars Act;
H.R. 938, BLOCKING Act of 2019 and HR 1506, FAIR Generics Act;
Hatch-Waxman Integrity Act of 2019, H.R. 990 and S. 344;
S. 1416, Affordable Prescriptions for Patients Act of 2019;
issues related to the pharmaceutical supply chain; and
issues related to FDA Abbreviated New Drug Application reviews of complex generics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review, including S. 2082, Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019 and H.R. 3666, STRONGER Patents Act of 2019;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilars in Part D, including H.R. 4913;
issues related to access to biosimilar biological products in Medicare Part B, including S. 4134, Increasing Access to Biosimilars Act of 2020.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, West Front Strategies LLC lobbied for Mylan Inc. , earning $70,000. The report was filed on Oct. 20, 2020.
Original Filing: 301221433.xml
Lobbying Issues
Issues related to drug pricing;
S. 64, Preserve Access to Affordable Generics and Biosimilars Act;
H.R. 938, BLOCKING Act of 2019 and HR 1506, FAIR Generics Act;
Hatch-Waxman Integrity Act of 2019, H.R. 990 and S. 344;
S. 1416, Affordable Prescriptions for Patients Act of 2019;
issues related to the pharmaceutical supply chain; and
issues related to FDA Abbreviated New Drug Application reviews of complex generics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review, including S. 2082, Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019 and H.R. 3666, STRONGER Patents Act of 2019;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilars in Part D, including H.R. 4913;
issues related to access to biosimilar biological products in Medicare Part B, including S. 4134, Increasing Access to Biosimilars Act of 2020.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, West Front Strategies LLC lobbied for Mylan Inc. , earning $70,000. The report was filed on July 20, 2020.
Original Filing: 301200669.xml
Lobbying Issues
Issues related to drug pricing;
S. 64, Preserve Access to Affordable Generics and Biosimilars Act;
H.R. 938, BLOCKING Act of 2019 and HR 1506, FAIR Generics Act;
Hatch-Waxman Integrity Act of 2019, H.R. 990 and S. 344;
S. 1416, Affordable Prescriptions for Patients Act of 2019;
issues related to the pharmaceutical supply chain; and
issues related to FDA Abbreviated New Drug Application reviews of complex generics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review, including S. 2082, Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019 and H.R. 3666, STRONGER Patents Act of 2019;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilars in Part D, including H.R. 4913;
issues related to access to biosimilar biological products in Medicare Part B.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, West Front Strategies LLC lobbied for Mylan Inc. , earning $70,000. The report was filed on April 20, 2020.
Original Filing: 301177528.xml
Lobbying Issues
Issues related to drug pricing;
Issues related to Risk Evaluation and Mitigation Strategies (REMS), including CREATES Act of 2019 - S. 340 and H.R. 965;
S. 64, Preserve Access to Affordable Generics and Biosimilars Act;
H.R. 938, BLOCKING Act of 2019 and HR 1506, FAIR Generics Act;
Hatch-Waxman Integrity Act of 2019, H.R. 990 and S. 344;
Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics, including Affordable Insulin Approvals Now Act, S. 2103;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review, including S. 2082, Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019 and H.R. 3666, STRONGER Patents Act of 2019;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilars in Part D, including H.R. 4913;
issues related to access to biosimilar biological products in Medicare Part B.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, West Front Strategies LLC lobbied for Mylan Inc. , earning $70,000. The report was filed on Jan. 21, 2020.
Original Filing: 301127701.xml
Lobbying Issues
Issues related to drug pricing;
Issues related to Risk Evaluation and Mitigation Strategies (REMS), including CREATES Act of 2019 - S. 340 and H.R. 965;
S. 64, Preserve Access to Affordable Generics and Biosimilars Act;
H.R. 938, BLOCKING Act of 2019 and HR 1506, FAIR Generics Act;
Hatch-Waxman Integrity Act of 2019, H.R. 990 and S. 344;
Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics, including Affordable Insulin Approvals Now Act, S. 2103;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review, including S. 2082, Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019 and H.R. 3666, STRONGER Patents Act of 2019;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty);
Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilars in Part D, including H.R. 4913.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, West Front Strategies LLC lobbied for Mylan Inc. , earning $70,000. The report was filed on Oct. 21, 2019.
Original Filing: 301077711.xml
Lobbying Issues
Issues related to drug pricing;
Issues related to Risk Evaluation and Mitigation Strategies (REMS), including CREATES Act of 2019 - S. 340 and H.R. 965;
S. 64, Preserve Access to Affordable Generics and Biosimilars Act;
H.R. 938, BLOCKING Act of 2019 and HR 1506, FAIR Generics Act;
Hatch-Waxman Integrity Act of 2019, H.R. 990 and S. 344;
Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review, including S. 2082, Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019 and H.R. 3666, STRONGER Patents Act of 2019;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty);
Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilars in Part D.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, West Front Strategies LLC lobbied for Mylan Inc. , earning $70,000. The report was filed on July 21, 2019.
Original Filing: 301053860.xml
Lobbying Issues
Issues related to drug pricing;
Issues related to Risk Evaluation and Mitigation Strategies (REMS), including CREATES Act of 2019 - S. 340 and H.R. 965;
S. 64, Preserve Access to Affordable Generics and Biosimilars Act;
H.R. 938, BLOCKING Act of 2019 and HR 1506, FAIR Generics Act;
Hatch-Waxman Integrity Act of 2019, H.R. 990 and S. 344;
Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review;
S. 1416, Affordable Prescriptions for Patients Act of 2019.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilars in Part D.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, West Front Strategies LLC lobbied for Mylan Inc. , earning $70,000. The report was filed on April 22, 2019.
Original Filing: 301034346.xml
Lobbying Issues
Issues related to drug pricing;
Issues related to Risk Evaluation and Mitigation Strategies (REMS), including CREATES Act of 2019 - S. 340 and H.R. 965;
S. 64, Preserve Access to Affordable Generics and Biosimilars Act;
H.R. 938, BLOCKING Act of 2019 and HR 1506, FAIR Generics Act;
Hatch-Waxman Integrity Act of 2019, H.R. 990 and S. 344;
Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review;
issues related to patentability.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Formulary placement of generics and biosimilars in Part D.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on Jan. 22, 2019.
Original Filing: 301017796.xml
Lobbying Issues
Issues related to the implementation of the Generic Drug User Fee Agreement;
issues related to drug pricing;
Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017; and
S. 124, Preserve Access to Affordable Generics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review;
Issues related to patentability.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical products in the proposed United States, Mexico, Canada Trade Agreement.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2018
In Q3, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on Oct. 13, 2018.
Original Filing: 300984997.xml
Lobbying Issues
Issues related to the implementation of the Generic Drug User Fee Agreement;
issues related to drug pricing;
Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017; and
S. 124, Preserve Access to Affordable Generics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical products in the proposed United States, Mexico, Canada Trade Agreement.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2018
In Q2, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on July 18, 2018.
Original Filing: 300968802.xml
Lobbying Issues
Issues related to the implementation of the Generic Drug User Fee Agreement;
issues related to drug pricing;
Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017; and
S. 124, Preserve Access to Affordable Generics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty)
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on April 19, 2018.
Original Filing: 300949349.xml
Lobbying Issues
Issues related to the implementation of the Generic Drug User Fee Agreement;
issues related to drug pricing;
Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017; and
S. 124, Preserve Access to Affordable Generics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty)
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929966.xml
Lobbying Issues
Issues related to the implementation of the Generic Drug User Fee Agreement;
issues related to drug pricing;
Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Medicaid Rebate provision of the Bipartisan Budget Act of 2015 (CPI Penalty)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on Oct. 18, 2017.
Original Filing: 300907482.xml
Lobbying Issues
Issues related to the implementation of the Generic Drug User Fee Agreement;
issues related to epinephrine auto injector pricing;
issues related to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inter Partes Review.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2017
In Q2, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on July 18, 2017.
Original Filing: 300888071.xml
Lobbying Issues
Issues related to the implementation of the Generic Drug User Fee Agreement;
issues related to epinephrine auto injector pricing;
issues related to drug pricing.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on April 18, 2017.
Original Filing: 300868466.xml
Lobbying Issues
Issues related to the implementation of the Generic Drug User Fee Agreement;
issues related to epinephrine auto injector pricing;
issues related to drug pricing.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on Jan. 23, 2017.
Original Filing: 300858258.xml
Lobbying Issues
Issues related to patent litigation reform, including H.R. 9, the Innovation Act; S. 632, the STRONG Patents Act; S. 1137, the PATENT Act; and, S. 2733, the Venue Equity and Non-Uniformity Elimination Act of 2016.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of the Generic Drug User Fee Agreement;
Issues related to H.R. 6, 21st Century Cures Initiative and Innovation for Healthier Americans Initiative;
Issues related to epinephrine auto injector pricing;
Issues related to generic drug pricing;
REMs program, H.R. 2841 FAST Generics Act and S.3056 CREATES Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to a Medicaid rebate for generic drugs, including provisions in the Bipartisan Budget Act of 2015 (H.R. 1314).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on Oct. 19, 2016.
Original Filing: 300834304.xml
Lobbying Issues
FY 2017 Agriculture/FDA Appropriations, in particular, FDA funding and issues related to user fees;
FY 2017 Labor/HHS Appropriations, in particular, issues related to Medicaid rebate for generic drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to patent litigation reform, including H.R. 9, the Innovation Act; S. 632, the STRONG Patents Act; S. 1137, the PATENT Act; and, S. 2733, the Venue Equity and Non-Uniformity Elimination Act of 2016.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of the Generic Drug User Fee Agreement;
Issues related to H.R. 6, 21st Century Cures Initiative and Senate HELP Innovation Initiative;
Issues related to epinephrine auto injectors;
FDA proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products;
FDA proposed rule, Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products;
Issues related to generic drug pricing;
Access to epinephrine auto injectors on air carriers, H.R. 4441, Aviation Innovation, Reform, and Reauthorization Act of 2016, and S. 2658, Federal Aviation Administration Reauthorization Act of 2016;
REMs program, H.R. 2841 FAST Generics Act and S.3056 CREATES Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the intellectual property provisions in the Trans-Pacific Partnership negotiations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to a Medicaid rebate for generic drugs, including provisions in the Bipartisan Budget Act of 2015 (H.R. 1314).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on July 19, 2016.
Original Filing: 300814012.xml
Lobbying Issues
FY 2017 Agriculture/FDA Appropriations, in particular, FDA funding and issues related to user fees;
FY 2017 Labor/HHS Appropriations, in particular, issues related to Medicaid rebate for generic drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to patent litigation reform, including H.R. 9, the Innovation Act; S. 632, the STRONG Patents Act; S. 1137, the PATENT Act; and, S. 2733, the Venue Equity and Non-Uniformity Elimination Act of 2016.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of the Generic Drug User Fee Agreement;
Issues related to H.R. 6, 21st Century Cures Initiative and Senate HELP Innovation Initiative;
FDA proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products;
FDA proposed rule, Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products;
Issues related to generic drug pricing;
Access to epinephrine auto injectors on air carriers, H.R. 4441, Aviation Innovation, Reform, and Reauthorization Act of 2016, and S. 2658, Federal Aviation Administration Reauthorization Act of 2016;
REMs program, H.R. 2841 FAST Generics Act and S.3056 CREATES Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the intellectual property provisions in the Trans-Pacific Partnership negotiations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to a Medicaid rebate for generic drugs, including provisions in the Bipartisan Budget Act of 2015 (H.R. 1314).
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on April 19, 2016.
Original Filing: 300796310.xml
Lobbying Issues
FY 2017 Agriculture/FDA Appropriations, in particular, FDA funding and issues related to user fees;
FY 2017 Labor/HHS Appropriations, in particular, issues related to Medicaid rebate for generic drugs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to patent litigation reform, including H.R. 9, the Innovation Act; S. 632, the STRONG Patents Act; and S. 1137, the PATENT Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of the Generic Drug User Fee Agreement;
Issues related to H.R. 6, 21st Century Cures Initiative and Senate HELP Innovation Initiative;
FDA proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products;
FDA proposed rule, Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products;
Issues related to generic drug pricing;
Access to epinephrine auto injectors on air carriers, H.R. 4441, Aviation Innovation, Reform, and Reauthorization Act of 2016, and S. 2658, Federal Aviation Administration Reauthorization Act of 2016;
REMs program, H.R. 2841 FAST generics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the intellectual property provisions in the Trans-Pacific Partnership negotiations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to a Medicaid rebate for generic drugs, including provisions in the Bipartisan Budget Act of 2015 (H.R. 1314).
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on Jan. 20, 2016.
Original Filing: 300782666.xml
Lobbying Issues
FY 2016 Agriculture/FDA Appropriations, in particular, FDA funding;
FY 2016 State/Foreign Operations Appropriations, in particular, PEPFAR funding.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to patent litigation reform, including H.R. 9, the Innovation Act; S. 632, the STRONG Patents Act; and S. 1137, the PATENT Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of the Generic Drug User Fee Agreement;
Issues related to H.R. 6, 21st Century Cures Initiative and Senate HELP Innovation Initiative;
FDA proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products;
FDA proposed rule, Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products;
Issues related to generic drug pricing;
Access to epinephrine auto injectors on air carriers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the intellectual property provisions in the Trans-Pacific Partnership negotiations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to a Medicaid rebate for generic drugs, including provisions in the Bipartisan Budget Act of 2015 (H.R. 1314).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on Oct. 19, 2015.
Original Filing: 300758021.xml
Lobbying Issues
FY 2016 Agriculture/FDA Appropriations, in particular, FDA funding and sequestration of user fees;
FY 2016 State/Foreign Operations Appropriations, in particular, PEPFAR funding.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to patent litigation reform, including H.R. 9, the Innovation Act; S. 632, the STRONG Patents Act; and S. 1137, the PATENT Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of the Generic Drug User Fee Agreement;
Issues related to H.R. 6, 21st Century Cures Initiative and Senate HELP Innovation Initiative;
FDA proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products;
FDA proposed rule, Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products;
Issues related to generic drug pricing;
Access to epinephrine auto injectors on air carriers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the intellectual property provisions in the Trans-Pacific Partnership negotiations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to the antitrust review of Teva Pharmaceuticals Industries, Ltd. offer to acquire Mylan N.V.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2015
In Q2, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on July 19, 2015.
Original Filing: 300740292.xml
Lobbying Issues
FY 2016 Agriculture/FDA Appropriations, in particular, FDA funding and sequestration of user fees;
FY 2016 State/Foreign Operations Appropriations, in particular, PEPFAR funding.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to patent litigation reform, including H.R. 9, the Innovation Act; S. 632, the STRONG Patents Act; and S. 1137, the PATENT Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of the Generic Drug User Fee Agreement;
Issues related to H.R. 6, 21st Century Cures Initiative and Senate HELP Innovation Initiative;
FDA proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products;
FDA proposed rule, Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products;
Issues related to generic drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the intellectual property provisions in the Trans-Pacific Partnership negotiations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to the antitrust review of Teva Pharmaceuticals Industries, Ltd. offer to acquire Mylan N.V.
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2015
In Q1, West Front Strategies LLC lobbied for Mylan Inc. , earning $60,000. The report was filed on April 20, 2015.
Original Filing: 300725240.xml
Lobbying Issues
FY 2016 Agriculture/FDA Appropriations, in particular, FDA funding and sequestration of user fees;
FY 2016 State/Foreign Operations Appropriations, in particular, PEPFAR funding.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to patent litigation reform, including H.R. 9, the Innovation Act and S. 632, the STRONG Patents Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of the Generic Drug User Fee Agreement;
Issues related to the 21st Century Cures Initiative and Innovation Initiative;
FDA proposed rule, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products;
FDA proposed rule, Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products;
Issues related to generic drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to the intellectual property provisions in the Trans-Pacific Partnership negotiations.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2015
West Front Strategies LLC filed a lobbying registration on Feb. 14, 2015 to represent Mylan Inc., effective Jan. 1, 2015.
Original Filing: 300710851.xml
Issue(s) they said they’d lobby about: FDA Appropriations; patent litigation reform; GDUFA implementation; 21st Century Cures initiative; PEPFAR; general corporate tax; intellectual property issues related to trade .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...